Cardiovascular Innovations and Applications

Cardiovascular Innovations and Applications A platinum open access & the official journal of the Great Wall International Congress of Cardiology

Cardiovascular Innovations and Applications (CVIA) publishes focused articles and original clinical research that explore novel developments in cardiovascular disease, effective control and rehabilitation in cardiovascular disease, and promote cardiovascular innovations and applications for the betterment of public health globally. The journal publishes basic research that has clinical applicability in order to promote timely communication of the latest insights relating to coronary artery disease, heart failure, hypertension, cardiac arrhythmia, prevention of cardiovascular disease with a heavy emphasis on risk factor modification. CVIA also welcomes commentaries, case studies and reports, letters to the editor, methodology papers related to clinical trials, education and training articles, techniques and videos. CVIA was founded on the occasion of the 25th anniversary of the GW-ICC in 2014 by Professor Dayi Hu, president of the GW-ICC and past president of the Chinese Society of Cardiology, and C. Richard Conti, MD, a past president of the American College of Cardiology and former Editor of Clinical Cardiology. The GW-ICC is one of the largest congresses in the Asian-Pacific region and is the most comprehensive and influential academic conference on cardiology. Held as a regular annual conference since 1990, GW-ICC has provided a platform for continuing education in cardiovascular disease diagnosis, treatment, and technology training, through events that leverage the expertise of internationally renowned cardiologists and scholars from the United States, Europe and Asia. The journal is published by Compuscript on behalf of the World Journals (Beijing) Medical Technology Co., Ltd. Compuscript is an international company based in Shannon, Ireland.

Using two-step   and   analyses, this   study identifies immune cell types that promote or protect against   (AD) and hi...
20/11/2025

Using two-step and analyses, this study identifies immune cell types that promote or protect against (AD) and highlights as a key mediator linking immune cell activity to AD risk.

:

Study uncovers immune cell and inflammatory protein links to aortic dissection, revealing potential therapeutic targets for better prevention and treatment.

This review in Cardiovascular Innovations and Applications - CVIA Journal discusses  -related cognitive impairment, high...
13/11/2025

This review in Cardiovascular Innovations and Applications - CVIA Journal discusses -related cognitive impairment, highlighting compromised kidney function, perioperative mechanisms in , and the importance of early intervention to prevent postoperative .

:

Chronic Kidney Disease patients face higher risks of cognitive decline after heart surgery. Exploring mechanisms behind this can improve outcomes and reduce complications.

This editorial highlights emerging insights into immune and   mechanisms driving   (AD), identifying key immune cell sub...
13/11/2025

This editorial highlights emerging insights into immune and mechanisms driving (AD), identifying key immune cell subsets and inflammatory proteins with causal roles in AD pathogenesis and therapeutic potential for precision . Fudan University

:

This editorial uncovers immune and inflammatory pathways driving aortic dissection, highlighting key cell subsets and proteins as potential therapeutic targets.

This editorial highlights the emerging role of immune regulation in  , emphasizing key genes   and   as novel diagnostic...
13/11/2025

This editorial highlights the emerging role of immune regulation in , emphasizing key genes and as novel diagnostic and therapeutic targets, and showcasing innovative , and cell-based strategies advancing . Zhengzhou University Boston University Chobanian & Avedisian School of Medicine

:

This editorial explores immune mechanisms in myocardial infarction, spotlighting S100A12 and BCL6 as key biomarkers driving next-gen precision cardiology.

This editorial highlights the emerging role of extracellular vesicle–derived   as ultra‑early   and therapeutic targets ...
11/11/2025

This editorial highlights the emerging role of extracellular vesicle–derived as ultra‑early and therapeutic targets in , marking a paradigm shift toward and personalized intervention in . .li.73 Harvard Medical School

:

This editorial discusses extracellular vesicle‑miRNAs as early biomarkers and therapeutic targets, redefining precision care in acute myocardial infarction.

This research letter integrates   and   analyses to identify   genes   and UBC as key regulators of   (MI) via  , reveal...
06/11/2025

This research letter integrates and analyses to identify genes and UBC as key regulators of (MI) via , revealing BCL2L1 as a promising therapeutic target for MI intervention.

:

This study explores PANoptosis as a therapeutic target for myocardial infarction using Mendelian randomization and multi-omics data analysis.

This   review provides an overview of the   &   of   (DCM) with insights into the complex interactions between   and imm...
30/10/2025

This review provides an overview of the & of (DCM) with insights into the complex interactions between and immune pathways in DCM, highlighting the potential of miRNA-based interventions in DCM management.

:

miRNAs play a key role in immune regulation in diabetic cardiomyopathy, offering potential therapeutic targets for improved treatment strategies.

This study developed   models to estimate peak VO₂ using non-exercise clinical data in   candidates, achieving strong pr...
24/10/2025

This study developed models to estimate peak VO₂ using non-exercise clinical data in candidates, achieving strong predictive accuracy and highlighting key predictors like TAPSE/PASP, proBNP, and —offering a practical alternative. Tunceli Devlet Hastanesi

:

ML models using non-exercise clinical data can estimate peak VO₂ in heart transplant candidates, aiding evaluation when CPET is not feasible.

A commentary discussing the use of   as first-line therapy for selected patients with   and  , covering current guidelin...
23/10/2025

A commentary discussing the use of as first-line therapy for selected patients with and , covering current guidelines, limitations, and future perspectives.

:

Advancements in atrial fibrillation therapy highlight catheter ablation as a key treatment, especially for select patients and those with heart failure.

This study shows that   (OSA) using  ‑guided   significantly improved QoR‑15 recovery scores, reduced pain, shortened   ...
16/10/2025

This study shows that (OSA) using ‑guided significantly improved QoR‑15 recovery scores, reduced pain, shortened time, and decreased hospital stay after , supporting OSA as an effective analgesic approach. Peking Union Medical College / Chinese Academy of Medical Sciences

: https://tinyurl.com/2dhf2pa5

This study reviews  , outlining its mechanisms, clinical impact, and prevention strategies, and highlights how modern   ...
09/10/2025

This study reviews , outlining its mechanisms, clinical impact, and prevention strategies, and highlights how modern and cardioprotective interventions enhance early detection and reduce in . East Tennessee State University

:

Explore Radiation-Induced Restrictive Cardiomyopathy: Advances in radiation therapy (3D-CRT, IMRT), DIBH, and protective medications (statins/ACEi) reduce cardiac risk.

This   study emphasizes the necessity and benefits of integrating   along with structured monitoring and detailed assess...
06/10/2025

This study emphasizes the necessity and benefits of integrating along with structured monitoring and detailed assessment in long-term management of advanced (HF) patients. Universiti Teknologi MARA Cawangan Selangor - Media Rasmi

Read the :

Cardiac Rehabilitation plays a crucial role in managing advanced heart failure, improving patient outcomes through multidisciplinary, long-term care strategies.

Address

Bay K, Shannon Industrial Estate
Shannon
V14WK53

Alerts

Be the first to know and let us send you an email when Cardiovascular Innovations and Applications posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Cardiovascular Innovations and Applications:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Cardiovascular Innovations and Applications (CVIA) was founded on the occasion of the 25th anniversary of the GW-ICC in 2014 by Professor Dayi Hu, president of the GW-ICC and past president of the Chinese Society of Cardiology, who will serve as Founding Editor. C. Richard Conti, MD, a past president of the American College of Cardiology and former Editor of Clinical Cardiology, has recently been appointed Editor-in-Chief of the new journal, which will publish its first issue to coincide with the GW-ICC meeting in October 2015 in Beijing, China.